May 7, 2025 12:58 PM EDTUpdated 01:19 PM

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

Alexis Kramer

Deputy Editor

Avadel Pharmaceuticals can try to expand the use of its blockbuster narcolepsy drug after a federal appeals court overturned an order that had barred it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Avadel can pur­sue la­bel ex­pan­sion for nar­colep­sy drug Lum­ryz af­ter court rul­ing

Deputy Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Avadel can pursue label expansion for narcolepsy drug Lumryz after court ruling